Call Us Today

Toll Free: (866) 328-7670 (866) 328-7670

Local: (504) 648-0180 (504) 648-0180

Pfizer to Pay $325 Million for the Wrongful Marketing of Neurontin

Pfizer Inc. agreed to a $325 million settlement to resolve claims alleging that it defrauded insurers and healthcare benefit providers by wrongfully promoting the epilepsy drug Neurontin for unapproved uses. James R. Dugan II of the Dugan Law Firm is part of the Plaintiffs’ Steering Committee in the multidistrict litigation.

The Neurontin settlement resolves a decade long civil lawsuit (In re Neurontin Marketing, Sales Practices, and Products Liability Litigation, U.S. District Court, District of Massachusetts, Nos. MDL 1629, 04-10981) against Pfizer and its Warner-Lambert Co unit for allegedly selling the drug for uses that were never approved by the FDA. The suit alleges that the drug maker wrongfully pushed sales of the drug to boost profit. Plaintiffs include those who purchased or reimbursed patients for the purchase of Neurontin or gabapentin, the chemical name of the drug.

The settlement is the latest development in litigation over the epilepsy drug. On April 21, Pfizer agreed to pay $190 million to settle claims alleging that it tried to prevent cheaper generic versions of the drug from hitting the market. In May 2004, the company plead guilty to criminal charges and forked out another $430 million over allegations that it illegally marketed Neurontin for headaches, pain and other unapproved uses.

Neurontin (gabapentin) is an anti-epileptic medication prescribed to control seizures and some types of pain associated with epilepsy in adults and children who are at least 12 years old. It is sometimes used for children with partial seizures between the ages of 3 and 12 as well as adults with nerve pain.

To learn more about Neurontin and/or the recent settlement, contact Dugan Law Firm.

Proud members of: